Robert “Bob” Jackson is an Operating Partner for Hildred Capital Management (HCM) and has been associated with HCM since 2018. Mr. Jackson is responsible for evaluating and managing private investment opportunities from a regulatory, manufacturing, and operations perspective. He is currently serving as the Chief Operating Officer for Pii, an HCM investment company specializing in Contract Development & Manufacturing Organization for branded and generic pharmaceuticals. Mr Jackson has also been closely involved with several other Hildred portfolio companies, including Crown Laboratories and Project Natural.
Mr. Jackson is the previous President of Global Innovative Product Development of Glenmark Pharmaceuticals, Inc. ("Glenmark”). Prior to Glenmark, Mr. Jackson served as Executive Vice President of Manufacturing Operations at Forest Labs. In his 14 years at Forest Labs, Mr. Jackson held a variety of positions with Research & Development ultimately being responsible for global drug product manufacturing at both internal (facilities in Dublin, Ireland and Cincinnati, USA) and external manufacturing sites located across the globe. Prior to Forest Labs, Mr. Jackson worked at Novartis in both Corporate Project Management and Research.
Bob and his wife Jane reside in Madison, NJ. They have a son and daughter both graduates of the University of Miami. Bob’s interests include spending extended time on a beach, skiing, and trying to improve his golf game.